These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 14596648)

  • 1. The use of mycophenolate mofetil in liver transplant recipients.
    Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
    Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil in kidney transplantation.
    Lui SL; Halloran PF
    Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualization of mycophenolate mofetil dose in renal transplant recipients.
    van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
    Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant patients.
    Salifu MO; Jindal RM
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):29-32. PubMed ID: 19371175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Mycophenolate Mofetil Suspension as Part of Induction Therapy After Living-Donor Liver Transplant.
    Harada N; Yoshizumi T; Yoshiya S; Takeishi K; Toshima T; Itoh S; Ikegami T; Fukuda M; Masuda S; Mori M
    Exp Clin Transplant; 2020 Aug; 18(4):485-490. PubMed ID: 32490763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
    Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
    J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.
    Torras J; Figueras J; Lama C; Fabregat J; Ramos E; Rafecas A; Gil-Vernet S; Pares D; Busquets J; Jaurrieta E
    Transplant Proc; 1999 Sep; 31(6):2430. PubMed ID: 10500656
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up.
    Gavlik A; Demirbas A; Tsaroucha A; Webb MG; Nery JR; Khan MF; Karatzas T; Khan RT; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997 Nov; 29(7):2971-2. PubMed ID: 9365633
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
    Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
    Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil: a unique immunosuppressive agent.
    Hood KA; Zarembski DG
    Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary induction with mycophenolate mofetil and corticosteroids in a liver transplant recipient with hepatorenal syndrome.
    Carr RR; Yoshida EM; Chung SW; Partovi N
    Ann Pharmacother; 1998 Jan; 32(1):45-8. PubMed ID: 9475819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.
    Young M; Plosker GL
    Pharmacoeconomics; 2002; 20(10):675-713. PubMed ID: 12162756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive regimens containing generic mycophenolate mofetil (Myfenax) in de novo renal transplant recipients--preliminary results of 6-month observation.
    Rutkowski B; Bzoma B; Dębska-Ślizień A; Chamienia A
    Ann Transplant; 2011; 16(4):74-80. PubMed ID: 22210425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
    Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
    Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.